Herpes Simplex Virus (HSV) hepatitis is a rare clinical entity that commonly leads to fulminant liver failure. Both HSV-1 and HSV-2 serotypes can cause hepatitis, which more commonly affects pregnant women and immunocompromised individuals. The development of fulminant liver failure frequently occurs without evidence of typical herpetic mucocutaneous lesions, making the diagnosis challenging. The development of HSV hepatitis has been reported in kidney, liver, pancreas, heart, and lung transplant recipients. 
| INTRODUC TI ON
Herpes Simplex Virus (HSV) hepatitis is a rare clinical entity that commonly leads to fulminant liver failure. Both HSV-1 and HSV-2 serotypes can cause hepatitis, which more commonly affects pregnant women and immunocompromised individuals. The development of fulminant liver failure frequently occurs without evidence of typical herpetic mucocutaneous lesions, making the diagnosis challenging. The development of HSV hepatitis has been reported in kidney, liver, pancreas, heart, and lung transplant recipients. [2] [3] [4] [5] Most commonly, this has occurred from either reactivation of latent HSV in the recipient or de novo primary infection. Much more rarely, donor transmission of HSV from the graft has been identified as the likely etiology. Here, we describe a case of probable donor-derived HSV-2 hepatitis in a kidney transplant recipient. The initial presentation of fulminant liver failure was successfully managed with acyclovir and supportive care. Interestingly and unique to this case, the severity of the initial liver injury has produced a phenotype of advanced stage fibrosis and portal hypertension, which has not been previously reported in the literature. 
| C A S E DE SCRIP TI ON

| Kidney transplant history
| Presentation with acute liver injury
Approximately seven months post kidney transplant, the patient presented with epigastric pain, nausea, vomiting, diarrhea and fevers. Initial laboratory values were significant for a white blood cell count of 17 × 10 9 /L, AST of 674 U/L, ALT of 557 U/L, and INR of 1.3. She was admitted to the hospital for further management.
Her tacrolimus was held due to high trough levels and concern for infection and she was initiated on IV ganciclovir due to concern for possible CMV hepatitis. No viral inclusions were seen on histology ( Figure 2A ). HSV PCR of hepatic tissue was not performed.
| Diagnosis and treatment of HSV hepatitis
After ongoing supportive care for approximately one week, the di- 
| Presentation with ascites and portal hypertension
Approximately three months after the initial presentation of acute hepatitis, she was readmitted to the hospital with increas- 
| CON CLUS ION
In the present case, we report a probable donor-derived HSV-2 infection leading to acute HSV hepatitis. The delayed timing of her presentation suggests that CMV prophylaxis with valganciclovir initially conferred protection. While she recovered from the initial acute liver injury, she has developed liver fibrosis and portal hypertension, unique among existing reports of HSV hepatitis.
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F I G U R E 3 Abdominal CT imaging with IV contrast 90 days after presentation with abdominal distension demonstrating a fibrotic liver with evidence of portal hypertension
